191 related articles for article (PubMed ID: 35279704)
1. Integrative metabolomic characterization identifies plasma metabolomic signature in the diagnosis of papillary thyroid cancer.
Yu S; Liu C; Hou Y; Li J; Guo Z; Chen X; Zhang L; Peng S; Hong S; Xu L; Li X; Liu R; Chen S; Li B; Weng Z; Li Y; Lv W; Yu J; Xiao H
Oncogene; 2022 Apr; 41(17):2422-2430. PubMed ID: 35279704
[TBL] [Abstract][Full Text] [Related]
2. Serum-plasma matched metabolomics for comprehensive characterization of benign thyroid nodule and papillary thyroid carcinoma.
Huang FQ; Li J; Jiang L; Wang FX; Alolga RN; Wang MJ; Min WJ; Ma G; Zhao YJ; Wang SL; Yu Y; Chen X; Zhu D; Zhu J; Wang G; Xia T; Sang JF; Lai MD; Li P; Zhu W; Qi LW
Int J Cancer; 2019 Feb; 144(4):868-876. PubMed ID: 30318614
[TBL] [Abstract][Full Text] [Related]
3. Cell-free DNA methylation biomarker for the diagnosis of papillary thyroid carcinoma.
Hong S; Lin B; Xu M; Zhang Q; Huo Z; Su M; Ma C; Liang J; Yu S; He Q; Su Z; Li Y; Liu R; Guo Z; Lv W; Xiao H
EBioMedicine; 2023 Apr; 90():104497. PubMed ID: 36868052
[TBL] [Abstract][Full Text] [Related]
4. Altered expression of DLG1-AS1 distinguished papillary thyroid carcinoma from benign thyroid nodules.
He T; Wang H; Sun J; Wu J; Gong F; Li S; Wang H; Li Y
BMC Endocr Disord; 2019 Nov; 19(1):122. PubMed ID: 31718630
[TBL] [Abstract][Full Text] [Related]
5.
Li J; Yin Y; Huang H; Li M; Li H; Zhang M; Jiang C; Yang R
Epigenomics; 2023 Dec; 15(23):1257-1272. PubMed ID: 38126720
[No Abstract] [Full Text] [Related]
6. Metabolic Profiles and Blood Biomarkers to Discriminate between Benign Thyroid Nodules and Papillary Carcinoma, Based on UHPLC-QTOF-ESI
Berinde GM; Socaciu AI; Socaciu MA; Petre GE; Socaciu C; Piciu D
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542465
[TBL] [Abstract][Full Text] [Related]
7. Distinguishing Benign and Malignant Thyroid Nodules and Identifying Lymph Node Metastasis in Papillary Thyroid Cancer by Plasma
Zhang Z; Reiding KR; Wu J; Li Z; Xu X
Front Endocrinol (Lausanne); 2021; 12():692910. PubMed ID: 34248851
[TBL] [Abstract][Full Text] [Related]
8. Metabolite analysis-aided diagnosis of papillary thyroid cancer.
Chen J; Hu Q; Hou H; Wang S; Zhang Y; Luo Y; Chen H; Deng H; Zhu H; Zhang L; Liu H; Wang A; Liu Y
Endocr Relat Cancer; 2019 Dec; 26(12):829-841. PubMed ID: 31671400
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic significance of elevated expression of HBME-1 in papillary thyroid carcinoma.
Chen YJ; Zhao RM; Zhao Q; Li BY; Ma QY; Li X; Chen X
Tumour Biol; 2016 Jul; 37(7):8715-20. PubMed ID: 26738867
[TBL] [Abstract][Full Text] [Related]
10. Altered Serum MicroRNA Profile May Serve as an Auxiliary Tool for Discriminating Aggressive Thyroid Carcinoma from Nonaggressive Thyroid Cancer and Benign Thyroid Nodules.
Zhang A; Wang C; Lu H; Chen X; Ba Y; Zhang C; Zhang CY
Dis Markers; 2019; 2019():3717683. PubMed ID: 31636734
[TBL] [Abstract][Full Text] [Related]
11. Exosomal miRNAs are potential diagnostic biomarkers between malignant and benign thyroid nodules based on next-generation sequencing.
Pan Q; Zhao J; Li M; Liu X; Xu Y; Li W; Wu S; Su Z
Carcinogenesis; 2020 Mar; 41(1):18-24. PubMed ID: 31560760
[TBL] [Abstract][Full Text] [Related]
12. Plasma metabolites analysis of patients with papillary thyroid cancer: A preliminary untargeted
Razavi SA; Mahmanzar M; Nobakht M Gh BF; Zamani Z; Nasiri S; Hedayati M
J Pharm Biomed Anal; 2024 Apr; 241():115946. PubMed ID: 38241910
[TBL] [Abstract][Full Text] [Related]
13. DNA Methylation Status of HYAL1 in Malignant and Benign Thyroid Nodules.
Li M; Yin Y; Zhang M; Jiang C; Li H; Yang R
Horm Metab Res; 2023 Dec; 55(12):869-875. PubMed ID: 38040022
[TBL] [Abstract][Full Text] [Related]
14. Metabolomics as a potential method for predicting thyroid malignancy in children and adolescents.
Zhou Q; Zhang LY; Xie C; Zhang ML; Wang YJ; Liu GH
Pediatr Surg Int; 2020 Feb; 36(2):145-153. PubMed ID: 31576470
[TBL] [Abstract][Full Text] [Related]
15. Serum microRNAs as biomarkers for the diagnosis of papillary thyroid carcinoma: a meta-analysis.
Chen Y; Dong B; Huang L; Huang H
Bosn J Basic Med Sci; 2022 Oct; 22(6):862-871. PubMed ID: 35678022
[TBL] [Abstract][Full Text] [Related]
16. High BRAFV600E mutation frequency in Chinese patients with papillary thyroid carcinoma increases diagnostic efficacy in cytologically indeterminate thyroid nodules.
Li XJ; Mao XD; Chen GF; Wang QF; Chu XQ; Hu X; Ding WB; Zeng Z; Wang JH; Xu SH; Liu C
Medicine (Baltimore); 2019 Jul; 98(28):e16343. PubMed ID: 31305422
[TBL] [Abstract][Full Text] [Related]
17. FNAB of benign thyroid nodules with papillary hyperplasia: a cytological and histological evaluation.
Pusztaszeri MP; Krane JF; Cibas ES; Daniels G; Faquin WC
Cancer Cytopathol; 2014 Sep; 122(9):666-77. PubMed ID: 24891128
[TBL] [Abstract][Full Text] [Related]
18. TROP-2 expression in papillary thyroid carcinoma: Potential Diagnostic Utility.
Simms A; Jacob RP; Cohen C; Siddiqui MT
Diagn Cytopathol; 2016 Jan; 44(1):26-31. PubMed ID: 26481593
[TBL] [Abstract][Full Text] [Related]
19. Combined metabolomic and lipidomic analysis uncovers metabolic profile and biomarkers for papillary thyroid carcinoma.
Wang Z; Yang Y; Xing Y; Si D; Wang S; Lin J; Li C; Zhang J; Yin D
Sci Rep; 2023 Oct; 13(1):17666. PubMed ID: 37848492
[TBL] [Abstract][Full Text] [Related]
20. Can malignant thyroid nodules be distinguished from benign thyroid nodules in children and adolescents by clinical characteristics? A review of 89 pediatric patients with thyroid nodules.
Buryk MA; Simons JP; Picarsic J; Monaco SE; Ozolek JA; Joyce J; Gurtunca N; Nikiforov YE; Feldman Witchel S
Thyroid; 2015 Apr; 25(4):392-400. PubMed ID: 25627462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]